Purpose: The purpose of this research was to identify novel genes that can be targeted as diagnostic and clinical markers of differentiated thyroid tumors.
INTRODUCTION
Differentiated thyroid epithelial tumors represent a spectrum of morphologically and biologically diverse lesions. The follicular-derived neoplasms (adenoma, carcinoma, and the follicular variant of papillary carcinoma) manifest overlapping cytomorphologic features and not infrequently pose diagnostic and treatment difficulties (1) (2) (3) (4) . Previous molecular studies of thyroid tumors have been limited to individual or multiple targeted markers and have failed to define any diagnostic or prognostic markers (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . Novel approaches are needed to identify reliable markers for pathological classification and to predict disease progression.
Parallel analysis of gene expression by microarray techniques offers a large-scale platform for screening tumors for novel markers for potential clinical applications. Using this approach, the biological and the molecular characteristics of several neoplastic entities, including a few thyroid neoplasms, have been defined (15) (16) (17) . To characterize the genetic events underlying the morphologic and biological heterogeneity of differentiated thyroid neoplasms, we performed gene expression analysis of histologically normal thyroid tissues from tumorand nontumor-bearing resections and benign and malignant follicular and papillary neoplasms.
MATERIALS AND METHODS
Tumor Samples. The samples for this study were taken from primary thyroid neoplasms and 6 nontumorous thyroid tissues (4 with matched tumor specimens) accessioned in the Department of Pathology at The University of Texas M.D. Anderson Cancer Center from 1996 to 2000. The study protocol was approved by the Institutional Review Board committee. The tumors included 4 follicular adenoma, 3 follicular carcinoma, 3 follicular variants of papillary carcinomas, and 2 conventional papillary carcinomas. The tissues were harvested immediately on arrival at the pathology suite, placed in liquid nitrogen, and stored at Ϫ80°C until used. Histopathologic diagnosis was performed according to the WHO guidelines.
cDNA Collection and Probes. Our platform consisted of 5,760 full-length cDNA clones from the Soares human infant brain 1NIB library (18) kindly provided by Genethon (Evry, France). Plasmids containing clones were grown in Escherichia coli by standard microbiologic methods. Each insert was (PCR) amplified (30 cycles) with vector primers derived by sampling 1 L of cell culture. PCR products were purified by EtOH precipitation, washed in 70% EtOH, dried, dissolved in 1 mmol/L EDTA/10 mmol/L Tris-HCl (pH 8; TE)/DMSO at 50:50 concentration and stored at Ϫ80°C. The quality, size, and concentration of PCR products were determined after agarose gel electrophoresis using Genetools software (Syngene; Merck Eurolab, Fontenay-sous-Bois, France) and were automatically annotated in the final differential expression data file.
Arraying. PCR products were arrayed on poly-L-lysinecoated slides (Menzel Glaser: CML, Nemours, France) using the Microgrid II pro arrayer (Biorobotics Ltd., Cambridgeshire, United Kingdom). Slides were packed and stored in a dark, dry place at room temperature until use.
Array Hybridizations. Before hybridization, the slides were hydrated over boiled water, dried for 3 seconds at 80°C, and exposed to UV irradiation (300 mJ, 254 nm) for DNA cross-linking. Slides were immersed in a freshly prepared blocking solution consisting of succinic anhydride (0.02 mmol/L) dissolved in 150 mL of 1-methyl-2-pyrrolidinone and 17 mL of sodium borate (0.2 mol/L; pH 8) and placed in an orbital shaker for 20 minutes. Slides were washed in H 2 O and were immersed in 100% EtOH at Ϫ20°C before a final 5-minute centrifugation at 500 rpm at room temperature. Slides were then prehybridized at 42°C in a 3ϫ SSC, 0.1% SDS, 0.1% bovine albumin for 30 minutes at 42°C, washed in H 2 O, and immersed and in isopropanol and absolute EtOH, successively. The slides were then centrifuged at 500 rpm for 5 minutes at room temperature.
RNA, cDNA, and Labeling. Total RNA was prepared using RNAplus according to the manufacturer's protocol (QBiogene, Illkirsch, France). For each competitive hybridization, total RNA from a clinical sample and the normal thyroid reference from Clontech (Palo Alto, CA) were labeled with Cy3-dUTP and Cy5-dUTP (Amersham Pharmacia Biotech, Saclay, France) by reverse transcription. For each reverse transcription reaction, 20 g of RNA was mixed with random hexamer (pdN6, Amersham Pharmacia Biotech; 2.5 g/mL) in a total volume of 15.5 L, heated at 65°C for 10 minutes, and placed on ice for at least 5 minutes. Unlabeled nucleotide pool (final concentration 500 mol/L each dATP, dCTP, dGTP, and 200 mol/L dTTP), either Cy3 or Cy5 conjugated dUTP (final concentration 66 mol/L; NEN, Saclay, France), 1ϫ first-strand Superscript II buffer, 10 mmol/L DTT, and reverse transcription (400 U; Superscript II; Life Technologies, Inc., Cergy-Pontoise, France) were added to a final volume of 30 L. After incubation at 42°C for 2 hours in a dark room, RNA was hydrolyzed by adding EDTA (45 mmol/L) and NaOH (180 mmol/L) and incubated at 65°C for 5 minutes. The mixture was neutralized by Tris-HCl (450 mmol/L; pH 7.5) and by adjusting the volume to 500 L with Tris-EDTA. Labeled cDNA was purified by centrifugation in a Microcon YM-30 (Amicon; Millipore, Bedford, MA) and eluted twice with 40 L of TE.
Hybridization. The Cy3 and Cy5-labeled cDNAs were mixed with 20 g human Cot-1 DNA, 20 g yeast tRNA (Life Technologies, Inc.) and 10 g poly(A; Sigma-Aldrich, SaintQuentin Fallavier, France), then precipitated with 0.5 volumes of 7.5 mol/L sodium acetate (pH 5.2) in EtOH. The pellet was dissolved in 60 L of hybridization solution (50% formamide, 2.5ϫ Denhardt's solution, 0.5% SDS, and 6ϫ SSPE. The probe was heated for 2 minutes at 100°C, incubated at 37°C for 20 to 30 minutes, and placed between slide and coverslip. The arrays were incubated overnight at 42°C in a custom humidified slide chamber. The slides were then washed in a first bath of 0.1ϫ SSC with 0.1% SDS for 5 minutes and then twice in 0.1ϫ SSC for 5 minutes at room temperature. The arrays were dried by centrifugation at 600 rpm for 10 minutes. As recommended, each hybridization was performed twice with reverse labeling (dye-swap; refs. 19 -21) .
Image Analysis and Array Quantification. Arrays were scanned using a two-color laser confocal scanner (GMS 418, Genetic Microsystems, Woburn, MA). Independent images were acquired for Cy3 (532 nm) and Cy5 (635 nm). Each spot was defined by automatic positioning of a grid using imageanalysis spot-tracking software (patent US 10/173,672 June, 19, 2002; CA 2,389,901 June, 20, 2002) . Each signal intensity was integrated Ͼ15 to 20 m square pixels and recorded in 16-bit format. For each spot and fluorochrome, the background and the signal pixels were segmented with a specific ExpectationMaximization algorithm, and finally the net signal intensity of a spot was obtained by subtracting calculated local background intensity from the signal intensity. The dye-swap hybridization allows us to estimate the reproducibility between the two independent measures obtained for either the reference thyroid or the clinical sample (21) . A reliability factor was calculated to compare the two measurements of a given spot and to score the reproducibility of signal intensities obtained for Cy3 C and Cy5 C. The reliability factor (i) factor of the i th spot is equal to the ratio of the two relative intensities measured for the i th spot (or inverse ratio if Ͼ1).
For additional intermicroarray comparisons and for calculating the expression ratio "clinical sample/thyroid reference," the series of paired Cy3 C and Cy5 C measures (each being already scored with its reliability factor) were corrected on the line of slope 1, and normalization was performed according to a set of constantly expressed genes (22) . A cutoff of 0.6 for reliability factor was used, considering that the two measures are reproducible.
The discrimination between two categories of samples, for example, thyroid adenomas and normal thyroid samples, is performed in two steps. The first step involves finding a set of genes that are differentially expressed within each category. The second step involves clusterizing samples according to this set of genes. The expression data are organized in a matrix N.P, where the N lines represent the genes and the P columns denote the samples. Each line of the matrix (vector line) is centered according to the following formula:
and normalized according to: Gene Clustering. To identify these genes that differentiate between two categories, we constructed two templates that represent the two theoretical vector lines. The first vector line has a value of 1 in all of the samples belonging to the first category and a value of Ϫ1 in samples belonging to the second category. The second vector line is the inverse of the first one with values of Ϫ1 in samples belonging to the first category and 1 for those belonging to the second category.
After centering and normalization of the data, the two templates and the experimental vector lines were clustered using locally developed software (ClusterIt, Paris, France)
All of the initiator vectors located at a weighted Euclidian distance inferior to a threshold s were grouped in the same cluster. If a vector also belonged to another cluster, there are two possible solutions. First, if this common vector is the initiator vector of one of the two clusters of interest then for each cluster, the mean of the vectors exclusively belonging to it is calculated. If the weighted Euclidian distance between the two means is inferior to the threshold S, the two clusters are grouped. If the distance is not inferior to the threshold, the two clusters are maintained as different clusters, and the common vectors are included in the nearest cluster (except if it is the initiator cluster). Secondly, if the common vector corresponds to a noninitiator vector, the vector is directly included in the closest cluster.
The threshold s is steadily decreased (s/100), and with each reduction, the same procedure is applied on each new cluster derived from the previous reduction. The initial threshold s is chosen such that s ϭ 2 ͱp corresponds to the highest distance existing between two centered and normalized vectors, where p is the number of columns of the matrix. The weighted Euclidian distance is defined as followed:
where
represents a vector line of the matrix,
the expression of the gene i in condition j (centered and normalized value), and
a weighting factor between 0 and 1 proportional to the reproducibility of each expression value (dye-swap experiments). The values of template vector lines are arbitrarily fixed at a very high level to force the experimental vector lines to clusterize with the templates. The final step of the cluster analysis corresponds to s ϭ 0, then each cluster is composed of a unique vector line. By following step by step the evolution of the cluster composition, it is possible to determine the lineage of each cluster and to define a hierarchical tree as a function of the cluster composition. In that context, attention was given to the two clusters, including the two template vector lines. To define at which s value (i.e., at what step), the composition of the cluster is homogeneous (see below), we developed two parameters Cd and RSC that permit the evaluation of cluster stability of a given:
where:
represents the real or the theoretical densities of probability of the distribution of the n vectors within the considered class, The definition of Cd and RSC factors are based on the following hypothesis: using DNA microarray, the error in the measure follows a normal distribution. Thus, as soon as a class of genes is homogeneous, a normal distribution of the vectors around the mean of all vectors within the class is expected. At the first step the clustering, defined with a threshold
, all of the gene vectors are grouped within the same cluster, and the mean vector of the entire cluster was null. The measured Cd could be Ͼ0.8 if the number of different vectors within the cluster is large enough to ensure, by hazard, a normal distribu-tion. The observed distribution resulted in a mixture of different classes of genes. Along with the steps of clustering and as s decreased, affiliated clusters segment and the number of vectors per cluster decreased, thus minimizing the probability of normal distribution due to hazard. At this point, the Cd coefficient becomes small (Ͻ0.8), and the vectors do not follow a normal distribution, because the number of mixed classes is not large enough to ensure a normal distribution due to the hazard. As soon as s is small enough to ensure that vectors belong to the same cluster and are homogeneous, Cd increases Ͼ0.8, the cluster is considered stable, and the vectors follow a normal distribution. At this step, the clustering could be improved by searching for the minimal RSC and checking vector by vector for the loss or gain of cluster stability. Specimen Clustering. Gene clusters, from the template vector line and the experimental vector lines, represent the set of genes that discriminate between two categories. For tumor classification, a new matrix excluding the previous template vector lines and adding two sample vector columns representing each of the two experimental categories were developed. The lines for the new columns were coded 1 for the first cluster of genes and Ϫ1 for the second cluster of genes. These two additional columns represent an experimental sample template for each category, whereas other columns correspond to the gene expression of the selected genes in each experimental sample. The vector lines of the transposed matrix organized around the vector template allowed for the construction of the hierarchical sample tree. For calculating the mean value of gene expression within each category, a matrix NЈ.Q is defined for a given category, where the NЈ lines represent the genes and the Q columns the different samples within the chosen category. For each gene, the weighted mean of expression was calculated according to the following equation:
where i and j represent, respectively, the indexes of lines and columns of the NЈ.Q matrix. And x the expression value at the (i,j) position of the matrix. The mean reproducibility factor is calculated according to the following equation:
Ͻ 0, where w is a weighting value between 0 and 1 proportional to the reproducibility of the expression value x.
We also investigated whether the follicular variant of papillary carcinoma can be distinguished from conventional papillary carcinoma by constructing 2 p vectors (p being the number of tumors) with the coordinates randomly equal to 1 or Ϫ1. The se vectors were organized in amatrix N.P, where the N lines represent the genes and the P columns the tumors. The five papillary tumors were randomly organized in the matrix, where each gene represents a vector. Within the homogeneous clusters of genes, we looked for clusters presenting two distinct levels of gene expression within these groups of tumors. We identified all of the clusters that permit the discrimination of one tumor against four or two tumors against three. We then grouped clusters that identify the same tumor, and, finally, we retained the group of clusters occurring at the highest frequency. With a such procedure, we constructed a reduced matrix NЈ. P and transposed the matrix to classify the five papillary tumors. Quantitative Real-Time Reverse Transcription-PCR. For several genes, mRNA expression was analyzed by real-time reverse transcription-PCR (ABI PRISM 7700 Sequence Detector apparatus, Applied Biosystems (Courtaboeuf, France). Firststrand cDNA synthesis was described previously, reactions were performed using Syber green incorporation (SYBR Green PCR Core Reagent, Perkin-Elmer), and quantification was performed using the dedicated software (Gene Amp software, PerkinElmer). Quantification of each gene expression was calibrated using a reference standard curve obtained by serial dilutions of PCR product prepared from a mixture of cDNAs from normal and tumorous thyroid samples handled separately but concomitantly with clinical samples. Gene expression was normalized as a function of the expression of the 18S rRNA, as described previously (23, 24) .
RESULTS
The patients and tumor characteristics are presented in Table 1 . As criteria for inclusion in the analysis, each array spot must be well measured in all of the samples. Accordingly, 4,287 spots satisfied such requirement in all of the specimens and formed the basis for the analysis. Thresholds of 2 and 0.5 were used as the mean expression ratio, for over-or underexpressed genes compared with the normal thyroid tissue, respectively. In the first phase of the analysis, the centered mean ratio of expression (tumor/reference) in different samples for each of the normal, adenoma, and follicular and papillary carcinomas was calculated for each spot.
Comparing the 6 normal thyroid specimens to the standard thyroid reference, 186 and 92 genes were found to be under-and overexpressed, respectively. Fig. 1A represents the main biological classifications of the differentially expressed genes, which are composed of the cytoskeleton, cell adhesion, and cellular matrix-related genes. Signal transduction and immuno-response genes accounted for 12% and 15% of the differentially expressed genes, respectively.
To determine neoplastic-associated genes, differentially altered genes between histologically normal thyroid tissues of tumor-and nontumor-bearing cases were excluded from the analysis. Accordingly, 4,101 well-measured genes in all of the tumor specimens applying the same centered mean of expression ratio (tumor/reference) were used. The number of differentially expressed genes in adenomas and follicular and papillary carcinomas were 615, 222, and 172, respectively (Table 1) . Fig. 1, A-D The gene differences between two tumors within a category were used to develop a strategy for the expression within a category independent of the expression ratio. In that strategy, a given gene can be used to discriminate between two categories without applying a strict cutoff if the expression ratio of this gene is as follows: (1) the same for all samples within a category, and (2) different between the two categories. As shown in Fig. 2, A and B, and Fig. 3, A and B, 23, 52 , and 80 genes define adenoma from papillary carcinoma, follicular carcinoma from follicular variant of papillary carcinoma, and adenomas from follicular carcinomas, respectively. The differentially expressed genes classifying follicular adenomas from follicular carcinomas are listed in Table 2 . Restricting gene clustering to the five papillary carcinomas, a set of genes (Table  3 ) differentiated the follicular variant from conventional papillary carcinomas (Fig. 3B) . Table 4 presents the quantitative real-time reverse transcription-PCR analysis of selected genes identified by microarray anal- 
DISCUSSION
Our study identified 186 (94 expressed sequence tags and 92 known genes) differentially expressed genes between normal tissues from tumor-and nontumor-bearing thyroid glands. Interestingly, the differentially expressed genes shared similar biological functions with those identified in follicular adenomas and included cytoskeleton, cell adhesion, cellular matrix, immune response stress-related, and signal transduction genes families. This finding, the first to our knowledge, suggests that thyroid tissue, from thyroid tumor-bearing patients, manifests genomic instability due to either engagement in the field of tumorigenesis or in response to tumor proximity. The data also show that adenomas can be differentiated from follicular carcinomas by a set of 43 genes of known functions. Of these, 10 were reported previously (17) to be highly expressed in follicular carcinomas (PEG10, PLCB4, FBN1, ID4, DUSP1, NID, BSG, CBS, HXB, RPP1, and TRAP240) and 3 genes (SORD, X123, MCG14797) in follicular adenomas (25, 26) . Granulin, a putative growth factor, was noted to be significantly overexpressed in carcinomas compared with adenomas. Previous studies of glioblastoma and gastric and ovarian cancers have also shown an up-regulation of this gene (27) (28) (29) . Of the down-regulated genes, DUSP 1, which has known proliferation and differentiation functions, has been shown previously to be down-regulated in follicular carcinomas (17) and in advanced epithelial ovarian cancer (30) . We also noted the PKIA gene, a potent inhibitor of protein kinase B, to be down-regulated in follicular carcinomas compared with adenomas, supporting previous molecular studies of sporadic thyroid cancer (31) . As in earlier studies, the VEGF gene was characteristically noted in follicular carcinomas (32, 33) .
Our study identified a set of 23 and 52 genes that differ- entiated papillary carcinoma from both follicular adenomas and carcinomas, respectively (Fig. 2, A and B) . These genes were composed of members of the protein metabolism/catabolism (15%), intracellular trafficking (12%), ion/metal binding and transport proteins (10%), and transcription related (12%) gene families. The Cyr61 gene was underexpressed in both papillary and follicular carcinomas ( Fig. 2A ) compared with adenomas, and it was shown previously to be down-regulated in papillary carcinomas (16) . Also MCM7, a DNA replication gene, was overexpressed in papillary carcinomas compared with adenomas. Although, the overall gene expressions of papillary and follicular carcinoma (Fig. 1) showed common features, we identified individual genes that differentiate between papillary and follicular carcinomas. Among these are the DUSP6 and DUSP5, members of the dual-specificity phosphatase gene family. DUSP5 has been reported previously to be up-regulated in premalignant lesions and underexpressed in invasive pancreatic carcinoma (34) . The MFGE8 gene that plays a key role in activities such as cell motility, activation, contact, and the maintenance of the membrane is also highly expressed in papillary carcinomas compared with adenomas. MFGE8 was shown previously to be highly overexpressed in human breast tumors (35) . Gene cluster analysis additionally segregated the conventional form from the follicular variant of papillary carcinomas (Fig. 3B) . Fourteen of these genes had transcriptional functions and included 2 of the Id4 and HOXC6, down-regulated and 12 (TRIM28, CUTL1, MSL3L1, SNW1, E64F1, CGBP, JUNB, ASCL1, IFGS3G, HCNGP, HCNP, and SSX1) overexpressed. Only a few of these genes have been reported previously to be associated with thyroid gland development. The Id4 expression, a dominant-negative transcriptional regulator, is known to be mainly expressed in thyroid (26) and to induce cell proliferation and inhibit differentiation induced by thyroid hormone (36) . The NR0B2 gene, a negative regulator of receptor-dependent signaling pathways, interacts with thyroid hormone and retinoid and thyroid hormone receptors to repress nuclear hormone receptor-mediated transactivation (37) .
Interestingly, the human ACSL1/HASH1 gene, a transcription factor that is overexpressed in the follicular variant of papillary carcinoma, has also been reported to be highly expressed in neuroendocrine tumors, including medullary thyroid and small cell lung cancers (38) . The finding suggests that the follicular variant, in contrast to the conventional form, preferentially manifest neuroendocrine features. The finding of underand overexpression of the NTRK2 and NTRK3 genes, respectively (Table 4) , and reports of medullary thyroid carcinoma support this hypothesis (39) . Similarly, the 2NF151/MIZ2I, CDK2API, and P12DOC-I genes, which are involved in cell proliferation (40, 41) , were found to be overexpressed in follicular variants than in conventional papillary carcinomas. The PEG10 gene was distinctly overexpressed in the follicular variant compared with the conventional papillary carcinoma. This gene has been reported to be highly expressed in hepatocellular carcinomas (42) and was found to differentiate follicular thyroid tumors from normal thyroid (17) . Cyclin D1 (CCND1), a regulatory subunit of CDK4 or CDK6, has been found to be overexpressed in papillary thyroid carcinomas (43) and predicts lymph node metastases in papillary thyroid carcinoma (44) .
In addition, the BGLAP, SPARC, and MSN genes, which bind to the Osteopontin (OPN) gene, were found to be distinctly overexpressed in the follicular variant of papillary carcinoma. These genes play a prominent role in bone and calcium metabolism and the formation of psammoma bodies in meningiomas (45) and ovarian serous papillary (46) and thyroid carcinomas (47) . In addition, SPARC and MSN are also associated with tumor invasiveness and metastasis (48, 49) . Tumor necrosis factor, a proinflammatory cytokine, TNFRSF25, a receptor expressed preferentially in tissues enriched with lymphocytes, NOTCH2, furin (PACE-1), GRB2, LNK, and HLA-DRB1 and HLA-DQA1, MHC-class II, were also overexpressed in follicular variants compared with papillary carcinomas. The expression of MHC class II was reported previously to be altered in papillary carcinomas, including the follicular variant (50) .
Our study shows that gene expression array analysis correlated generally with classification of thyroid tumors. We also identified a set of genes that are differentially expressed between follicular benign and malignant neoplasms and between these tumors and papillary carcinoma. Although interesting, the final verification of the true biological nature must await additional follow-up on these patients. 
